ST1571: A paradigm for clinical trials of molecularly targeted agents

Biomedicine and Pharmacotherapy

Volumn 55, Issue 9-10, 2001, Pages 529-530

  Druker, B J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERFERON; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE C KIT; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE MODEL; DOSE RESPONSE; DRUG RESPONSE; ENZYME ACTIVITY; GLIOBLASTOMA; GROWTH INHIBITION; HEMATOPOIETIC CELL; HUMAN; IN VITRO STUDY; LUNG SMALL CELL CANCER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING;

EID: 0035652202     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(01)00137-8     Document Type: Article

References (17)

1. A minute chromosome in human chronic granulocytic leukemia
2. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
3. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
4. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
5. Acute leukemia in bcr/abl transgenic mice
6. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
7. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
8. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
9. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
10. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
11. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcr-Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis
12. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins
13. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
14. Protein tyrosine kinases and cancer
15. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
16. The selective tyrosine kinase inhibitor ST1571 inhibits small cell lung cancer growth
17. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor ST1571